Company Overview and News

 
Airbus, Lockheed Rush to Tap India's $620 Billion Defense Market - Bloomberg

2018-04-11 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Upvote Downvote

 
Centrum Capital Limited - Shareholders meeting

2018-04-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
Upvote Downvote

 
Centrum Capital Limited - Updates

2018-04-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
Upvote Downvote

 
Centrum Capital on radar as it sells forex arm

2018-04-03 thehindubusinessline
Shares of Centrum Capital will remain in investors’ focus, as the Centrum group has decided to exit its forex business under the brand name Centrum Direct, by selling it to Atlanta-based Ebix Inc for about ₹1,200 crore. As part of the deal, the entire Centrum Direct team and assets will be transferred to Ebix and will become part of EbixCash, an end-to-end financial exchange.
Upvote Downvote

 
Ebix Takes Leadership Position in India’s Foreign Exchange and Outward Remittance Markets with Agreement to Acquire CentrumDirect Limited

2018-04-03 globenewswire
JOHNS CREEK, Ga., April 03, 2018 (GLOBE NEWSWIRE) -- Ebix, Inc. (NASDAQ:EBIX), a leading international supplier of On-Demand software and E-commerce services to the insurance, financial, e-governance and healthcare industries, today announced that it has entered into an agreement to acquire India based CentrumDirect Limited (CDL), the undisputed Leader in India’s Foreign Exchange and outward remittance markets for approximately $175 million.
Upvote Downvote

 
UPDATE 1-India's Centrum Group to sell money exchange business to US-based Ebix

2018-04-03 reuters
April 3 (Reuters) - India’s Centrum Capital Ltd said on Tuesday its parent Centrum Group had agreed to sell its money exchange business, Centrum Direct, to U.S.-based Ebix Inc for about 12 billion rupees ($184.6 million).
Upvote Downvote

 
Centrum group to sell money exchange business to US-based Ebix

2018-04-03 livemint
Bengaluru: India’s Centrum Capital Ltd said on Tuesday the parent Centrum group agreed to sell its money exchange business to US-based Ebix Inc for about Rs1,200 crore ($184.60 million).
Upvote Downvote

 
India's Centrum Group to sell money exchange business to U.S.-based Ebix

2018-04-03 reuters
April 3 (Reuters) - India’s Centrum Capital Ltd said on Tuesday the parent Centrum group agreed to sell its money exchange business to U.S.-based Ebix Inc for about 12 billion rupees ($184.60 million).
Upvote Downvote

 
Centrum Group looks to enter insurance, stressed assets business

2018-03-13 livemint
Mumbai: Centrum Group is exploring entry into new lines of business such as stressed assets and insurance, even as the group is looking to boost its existing lending businesses with a fund-raise of around Rs500 crore.
Upvote Downvote

 
Market Live: Sensex, Nifty steady around day#39;s high points; metals rally

2018-01-04 moneycontrol
2:24 pm Market Check: Benchmark indices have continued to hold on to the strong momentum, with the Sensex trading over 100 points higher, while the Nifty is hovering near the 10,500-mark.
Upvote Downvote

 
Market Live: Sensex extends gains, Nifty nears 10,500; Europe opens higher

2018-01-04 moneycontrol
1:55 pm Europe higher: European markets opened higher on Thursday morning, as investors reacted to robust economic data from both sides of the Atlantic, while oil prices hovered around two-and-a-half year highs amid unrest in Iran.
Upvote Downvote

 
Top buzzing midcap stocks to trade on December 4

2018-01-04 moneycontrol
Here are a few top buzzing midcap stocks picked by CNBC-TV18's analysts in trade today. We have - Dr Reddys, ONGC, Tata Motors, Bank of Maharashtra, Centrum Capital, Aurionpro, Nitesh Estates, SJVN and Unichem Labs.
Upvote Downvote

 
Centrum Capital gains 4% as board approves fund raising worth Rs 18000cr

2018-01-04 moneycontrol
Shares of Centrum Capital rose 4.5 percent intraday Thursday as the company is going raise Rs 18000 crore.
Upvote Downvote

 
Syndicate Bank seeks up to $186.4 million in share sale : Sources

2017-12-12 moneycontrol
Indian state-run Syndicate Bank Ltd has launched a share sale to institutional investors, seeking to raise up to 12 billion rupees (USD 186.4 million) to help boost its capital ratio, sources with direct knowledge said on Tuesday.
Upvote Downvote

 
Syndicate Bank seeks up to $186.4 million in share sale - sources

2017-12-12 in.reuters
MUMBAI (Reuters) - Indian state-run Syndicate Bank Ltd has launched a share sale to institutional investors, seeking to raise up to 12 billion rupees ($186.4 million) to help boost its capital ratio, sources with direct knowledge said on Tuesday.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...